Pharmafile Logo
Pharmafocus logo
Advanced Search

ViiV

Showing 11 posts of 26 posts found.

GSK image

Generics continue to erode GSK sales

May 6, 2015
Sales and Marketing GSK, HIV, Novartis, Q1, ViiV, Witty, hampton, respiratory

GlaxoSmithKline’s pharma sales continued to slide in the first quarter of 2015, but ViiV healthcare and the portfolios acquired from …

News
GSK image

GSK blames respiratory woes as sales drop

February 5, 2015
Sales and Marketing Advair, GSK, GlaxoSmithKline, HIV, ViiV, Witty, anoro ellipta, breo, lovaza, q4, sales

GlaxoSmithKline’s respiratory business has been flagged as the key factor in the firm’s fourth quarter financial misfortunes, as its total …

News
Viiv image

GSK mulls $27 billion ViiV sell-off

October 23, 2014
Medical Communications, Sales and Marketing AIDS, Advair, GSK, HIV, Pfizer, Q3, Shionogi, Tivicay, ViiV

After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing …

News
gsk_through_window

Pharma’s reputation ‘getting worse’

February 17, 2014
Medical Communications, Sales and Marketing GSK, Gilead, Pfizer, ViiV, patientview, pharma, reputation

The pharma industry’s reputation is getting worse – at least, in the eyes of 800 patient groups – according to …

News
GSK image

HIV pill Tivicay gains FDA approval

August 14, 2013
Sales and Marketing FDA, GSK, Tivicay, ViiV

ViiV and partner GlaxoSmithKline’s new HIV drug Tivicay has been shown the FDA’s green light for distribution in the US. …

News

ViiV HIV drug boost

February 18, 2013
Sales and Marketing Dolutegravir, GSK, HIV, ViiV

ViiV Healthcare has received a boost with the news that the FDA is to give a priority review to its …

News

Shionogi and ViiV strike new HIV deal

October 30, 2012
Research and Development, Sales and Marketing Atripla, Dolutegravir, HIV, Shionogi, ViiV

HIV specialist firm ViiV Healthcare has announced a new deal with Japan’s Shionogi on a promising new treatment. ViiV Healthcare …

News

ViiV Healthcare appoints Just:: Health PR

April 12, 2012
Medical Communications, Sales and Marketing HIV/AIDS, Just::, PR, ViiV

ViiV Healthcare has appointed Just:: Health PR to work on an integrated political and public relations initiative that will engage …

News
viiv_gsk_pfizer_david_redfern

David Redfern appointed ViiV chairman

February 28, 2011
Research and Development, Sales and Marketing David Redfern, GSK, GlaxoSmithKline, Pfizer, ViiV, ViiV Healthcare, appointment, research and development, sales and marketing

David Redfern has been appointed as chairman of ViiV Healthcare, the joint GlaxoSmithKline-Pfizer venture focused on HIV.

Appointment
Shire's ADHD website

Digital Pharma: Byte-sized roundup

January 8, 2010
Medical Communications Diabetes UK, NICE, Shire, ViiV, digital pharma, doctors.net, iphone

Includes online petition against NICE decision, Shire brings ADHD to Twitter, ViiV joins Twitter, Doctors.net.uk launches iPhone app and Diabetes …

News

GlaxoSmithKline-Pfizer launch HIV joint venture

November 4, 2009
Research and Development, Sales and Marketing GSK, HIV, Pfizer, ViiV

GlaxoSmithKline and Pfizer have launched a specialist HIV company with access to ten medicines developed by the two manufacturers.ViiV Healthcare, …

News

Latest content

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024

Merck to acquire Mirus Bio for $600m

May 23, 2024

Rare disease clinical trials: the urgent need for patients to be heard

May 22, 2024